IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma

• Published in: British journal of haematology 2008-04, Vol.141 (2), p.244-248
• Main Authors: Fox, C. P., McMillan, A. K., Bishton, M. J., Haynes, A. P., Russell, N. H.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antigens, CD34 - analysis; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; autologous stem cell transplantation; Biological and medical sciences; Carboplatin - therapeutic use; chemotherapy; Drug Evaluation; Epirubicin - therapeutic use; Etoposide - therapeutic use; Female; Hematologic and hematopoietic diseases; Hematopoietic Stem Cell Mobilization - methods; Humans; Ifosfamide - therapeutic use; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; lymphoma; Lymphoma - drug therapy; Lymphoma - therapy; Male; Medical sciences; Middle Aged; Peripheral Blood Stem Cell Transplantation - methods; Retrospective Studies; salvage therapy; Salvage Therapy - methods; stem cell mobilisation; Treatment Outcome
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/j.1365-2141.2008.07068.x

Summary Two commonly used chemotherapy regimens for lymphoma salvage therapy were compared: ICE (ifosphamide, carboplatin and etoposide) ± rituximab and IVE (ifosfamide, epirubicin and etoposide) ± rituximab, for their efficacy in mobilising peripheral blood stem cells for autologous transplantation. Significant differences were observed between the cohorts in terms of number of patients mobilising the stipulated minimum >2 × 106 CD34+/kg (99·2% in IVE group versus 83% in ICE group: P = 0·0002) and also in terms of the number of patients achieving the predetermined target of >5 × 106 CD34+/kg, both in total and during the first apheresis procedure (72% in IVE versus 51% in ICE group and 49% in IVE versus 7% in ICE group: P = 0·02 and P